Back to Newsroom

Corbus Pharmaceuticals Appoints Charles N. Serhan, Ph.D., to Scientific Advisory Board

NORWOOD, MA — (Marketwired) — 05/14/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the “Company”), a clinical stage drug development company targeting rare, life-threatening chronic inflammatory and fibrotic diseases, announced today that it has appointed Charles N. Serhan, Ph.D., to the Company’s Scientific Advisory Board (“SAB”). Dr. Serhan is a leading authority in inflammatory resolution and was the first to identify the role of anti-inflammatory cellular mediators such as resolvins and lipoxins in the pro-inflammatory pathway.

Click here to read more